Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 2136-2143, 2007. First published October 5, 2007; 10.1373/clinchem.2007.091413
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 091413.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2007.091413v1
53/12/2136    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goodwin, R. S.
Right arrow Articles by Huestis, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goodwin, R. S.
Right arrow Articles by Huestis, M. A.
Related Collections
Right arrow General Clinical Chemistry
Right arrow Pediatric Clinical Chemistry
Right arrow Informatics and Statistics
Right arrow Drug Monitoring and Toxicology
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2007;53:2136-2143.)
© 2007 American Association for Clinical Chemistry, Inc.

Drug Monitoring and Toxicology

Buprenorphine and Norbuprenorphine in Hair of Pregnant Women and Their Infants after Controlled Buprenorphine Administration

Robert S. Goodwin1, Diana G. Wilkins2, Olga Averin2, Robin E. Choo1,3, Jennifer R. Schroeder4, Donald R. Jasinski5, Rolley E. Johnson6, Hendrée E. Jones7 and Marilyn A. Huestis1,a

1 Chemistry and Drug Metabolism Section, National Institute on Drug Abuse–Intramural Research Program, National Institutes of Health, Baltimore, MD.
2 Center for Human Toxicology, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT.
3 Department of Biology, University of Pittsburgh at Titusville, Titusville, PA.
4 Office of the Clinical Director, National Institute on Drug Abuse–Intramural Research Program, National Institutes of Health, Baltimore, MD.
5 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
6 Reckitt Benckiser Pharmaceuticals, Inc., Richmond, VA.
7 Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD.

aAddress correspondence to this author at: Chief, Chemistry and Drug Metabolism, National Institute on Drug Abuse–Intramural Research Program, National Institutes of Health, 5500 Nathan Shock Dr., Baltimore, MD 21224. Fax 410-550-2971; e-mail mhuestis{at}intra.nida.nih.gov.

Background: Buprenorphine is under investigation as a pharmacotherapeutic agent for treating opioid dependence in pregnant women. We hypothesized that there would be a relationship between the cumulative maternal dose of buprenorphine during pregnancy and the concentration of buprenorphine and norbuprenorphine in maternal and infant hair.

Methods: This study examined buprenorphine and norbuprenorphine concentrations in hair obtained from 9 buprenorphine-maintained pregnant women and 4 of their infants. Specimens were analyzed by liquid chromatography-tandem mass spectrometry with limits of quantification of 3.0 pg/mg. All maternal hair specimens were washed with methylene chloride before analysis, and when sufficient amounts of maternal hair were available, specimens also were analyzed without washing. Infant hair specimens were not washed.

Results: Buprenorphine concentrations were significantly greater in unwashed hair than washed hair (P = 0.031). Norbuprenorphine concentrations were significantly greater than buprenorphine concentrations in both maternal (P = 0.0097) and infant hair (P = 0.0033). There were statistically significant associations between the cumulative maternal dose of buprenorphine administered and the concentrations of buprenorphine (washed, P <0.0001; unwashed, P = 0.0004), norbuprenorphine (washed, P <0.0001; unwashed, P = 0.0005), and buprenorphine plus norbuprenorphine (washed, P <0.0001; unwashed, P = 0.0005) for both washed and unwashed maternal hair specimens. There was a significant positive association between concentrations of buprenorphine and norbuprenorphine in maternal hair (washed, P <0.0001; unwashed, P = 0.0003), a trend for this association in infant hair (P = 0.08), and an association between buprenorphine concentrations in maternal unwashed hair and infant hair (P = 0.0002). The buprenorphine:norbuprenorphine ratio increased in distal segments.

Conclusion: Buprenorphine treatment during gestation provides an opportunity for monitoring drug disposition in maternal and fetal tissues under controlled conditions.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.